Listen: #JPM22 in review, Biogen’s worsening fortunes, & the future of RNA drugs

Was J.P. Morgan a drag? Is it time to give up on Aduhelm? And how many guitars is too many?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT health tech correspondent Katie Palmer joins us to recap the J.P. Morgan Healthcare Conference. Then, we discuss the latest twist in Biogen’s quest to expand the use of Aduhelm and what it means for the treatment of Alzheimer’s disease. Finally, Arrakis Therapeutics CEO Michael Gilman calls in to explain how targeting RNA can treat disease and why the characters in “Dune” don’t just shoot each other with laser guns.

For more on what we cover, here’s a look at J.P. Morgan; here’s the latest on Aduhelm; here’s more on Arrakis; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.

Be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].